Within the framework of the priority agenda of the Ministry of Health during this period of summer of 2025the Government held a meeting with representatives of transnational laboratories and reached a collaboration and work agreement to develop the pneumococcus vaccine.
The national minister participated in the call held this Wednesday Mario Lugones with authorities of the Pan American Health Organization (PAHO/WHO), of Pfizer and Sinergium Biotech, in order to constitute a joint scheme to guarantee the integral production of the Twenty-valent Pneumococcal Conjugate Vaccine (VCN20) and thus extend the distribution of coverage at the national level and export the vaccine to countries in the region.
During the meeting, the health organization agreed to highly complex technology transfer to expand production of the vaccine, as well as a state investment of around US$20 million intended for training, engineering works and acquisition of cutting-edge equipment.
The local production of VCN20 will make it possible for Argentina to become the first producing country in Latin America. The foreign exchange that would enter the national coffers would amount to about US$100 million for the distribution of vaccines to all of Americathrough the Revolving Fund that guarantees transparency and accessibility.
As reported by the Ministry of Health“The new vaccine incorporates 7 serotypes that are responsible for causing invasive pneumococcal disease (IPD) in children in countries with existing pneumococcal vaccination programs.
Vaccination against dengue: registration in Buenos Aires
The youths from among 20 and 24 years old will be able to get vaccinated against dengue in the city of Buenos Aires that wants to ensure the protection of the health of the neighbors and the shifts will be requested on the website of the Buenos Aires government.
On this occasion, the city of Buenos Aires accompanies the recommendations of the National Immunization Commission, based on which the Ministry of Health of the Nation In coordination with the provinces, it defined the national guidelines for the vaccination campaign free of charge.
The vaccine that will be used is Qdenga which was approved by the ANMAT in 2023 and developed by the Takeda laboratory. Its use was approved after efficacy and safety studies (phase III), and phase IV studies will be carried out in 2025.
On the other hand, from the City Government announced that the vaccination plan will be developed progressively and in stages, in line with national guidelines and subject to the availability of vaccines. Although, they mentioned that vaccination is not indicated for immunosuppressed patients, pregnant women, breastfeeding women, children under 4 years of age and over 60 years of age.
Source: Ambito
David William is a talented author who has made a name for himself in the world of writing. He is a professional author who writes on a wide range of topics, from general interest to opinion news. David is currently working as a writer at 24 hours worlds where he brings his unique perspective and in-depth research to his articles, making them both informative and engaging.
